LVW Advisors LLC Trims Holdings in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB)

LVW Advisors LLC decreased its stake in shares of Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) by 1.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 632,516 shares of the company’s stock after selling 8,523 shares during the quarter. LVW Advisors LLC owned about 2.44% of Anebulo Pharmaceuticals worth $1,063,000 at the end of the most recent reporting period.

Anebulo Pharmaceuticals Stock Down 1.5 %

NASDAQ:ANEB opened at $1.59 on Monday. Anebulo Pharmaceuticals, Inc. has a 52 week low of $0.80 and a 52 week high of $3.30. The company has a market capitalization of $41.23 million, a P/E ratio of -5.30 and a beta of -1.14. The stock’s fifty day moving average is $1.50 and its two-hundred day moving average is $1.85.

Analysts Set New Price Targets

Separately, Benchmark reiterated a “speculative buy” rating and set a $8.00 price objective on shares of Anebulo Pharmaceuticals in a research report on Tuesday, November 19th.

Insider Buying and Selling at Anebulo Pharmaceuticals

In other Anebulo Pharmaceuticals news, Director Aron R. English bought 10,101,010 shares of Anebulo Pharmaceuticals stock in a transaction on Monday, December 23rd. The shares were bought at an average price of $0.99 per share, for a total transaction of $9,999,999.90. Following the completion of the transaction, the director now directly owns 15,467,300 shares of the company’s stock, valued at $15,312,627. This trade represents a 188.23 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 85.90% of the company’s stock.

Anebulo Pharmaceuticals Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.